RETRACTION

Matrine Suppresses the Migration and Invasion of NSCLC Cells by Inhibiting PAX2-Induced Epithelial-Mesenchymal Transition [Retraction]

Yang J, He D, Peng Y, et al. OncoTargets and Therapy. 2017;10:5209-5217.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Following the authors request to make corrections an investigation found several images within Figures 2 and 5 appeared to have been duplicated.

- Figure 2A, A549, Migration, (0mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Migration, (0.5mg/mL); Invasion (0mg/mL); Invasion, (0.5mg/mL) and Figure 2B, H1299, Invasion, (0mg/mL).
- Figure 2A, A549, Migration, (1mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Invasion, (1mg/mL) and Figure 2B, H1299, Migration, (1mg/mL).
- Figure 5C, A459, GAPDH, appears to have been duplicated with the same image for Figure 5D, H1299, GAPDH.

The authors cooperated with the investigation and provided data associated with the study. However, despite the authors' assistance, they were unable to provide a satisfactory explanation for how the images came to be duplicated, and the validity of the published work could not be verified. The decision was made to retract the article and the authors agreed with this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

213

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.\$414610

OncoTargets and Therapy 2023:16 213

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work are permitted without any further permission form Dove Medical Press Limited, provided the work is properly attributed.